Skip to Content
Merck
All Photos(1)

Key Documents

SML0900

Sigma-Aldrich

ZLN024

≥98% (HPLC)

Synonym(s):

2-[[2-(2-Bromo-4-methylphenoxy)ethyl]thio]-pyrimidine

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
RM 401.00

RM 401.00

Estimated to ship on18 April 2025

Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
RM 401.00

About This Item

Empirical Formula (Hill Notation):
C13H13BrN2OS
CAS Number:
723249-01-2
Molecular Weight:
325.22
UNSPSC Code:
12352202
NACRES:
NA.77

RM 401.00

Estimated to ship on18 April 2025

Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

S(CCOc2c(cc(cc2)C)Br)c1ncccn1

InChI

1S/C13H13BrN2OS/c1-10-3-4-12(11(14)9-10)17-7-8-18-13-15-5-2-6-16-13/h2-6,9H,7-8H2,1H3

InChI key

KWJRSHZSULRJHE-UHFFFAOYSA-N

Biochem/physiol Actions

ZLN024 is an allosteric activator of AMPK hetero-trimers.
ZLN024 is an allosteric activator of AMPK hetero-trimers. The compound ZLN024 protects against dephosphorylation of Thr172, which is critical for activity, and antagonizes AMPK autoinhibition. ZLM024 improves glucose tolerance and lowers total cholesterol levels in db/db mice.

Pictograms

CorrosionExclamation mark
GHS05,GHS07

Signal Word

Danger

Hazard Statements

H302,H315,H318,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
123M4717V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tereza Moore et al.
PloS one, 15(10), e0240517-e0240517 (2020-10-15)
Mitochondrial diseases are a clinically heterogenous group of disorders caused by respiratory chain dysfunction and associated with progressive, multi-systemic phenotype. There is no effective treatment or cure, and no FDA-approved drug for treating mitochondrial disease. To identify and characterize potential

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service